On Nov. 25, 2020, RedHill Biopharma announced partnerships with two leading, U.S.-based manufacturers for large-scale manufacturing of opaganib.

These collaborations further advanced ongoing preparations to support potential emergency use applications for opaganib to treat severe COVID-19 pneumonia, was expected as early as the first quarter of 2021.